We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Trellus Health Plc | TRLS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.15 | 8.57% | 1.90 | 11:00:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.75 | 1.75 | 1.90 | 1.90 | 1.75 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 03/10/2023 16:10 by hatfullofsky I was waiting for the user numbers too and to hear they have moved the 130 [paying] members $100 / month to a free service as part of a community feedback programme really hurt. There is clearly no demand in the D2C model and that's why they pushed the B2B emphasis on the investor call.If this tool does save money for the payer there is a clear business case. You could see the health care provider making it mandatory for all IBS / IBD sufferers. But the "potential share of savings" being the "significant upside" worries me when they have no users yet 6,200 members at $1,250 is breakeven £7.75m so current cash levels support the 2025 timeline. Their current pilot programmes have a TAM of 325 users and we'll only get results in Q2-24. They alluded to signing a major pilot programme (I guess before year end), that will attract interest and then the results in Q2 but really we are going to be waiting a long time for this to ignite |
Posted at 03/10/2023 09:37 by seadog40 Watched the investor call. Totally underwhelmed, but in absence of sensible user numbers/revenue there's not much else to say. The founder sounds very good and all the hard ground work seems to have been done. It's basically trading at the value of the cash held (about £11.5 my calc versus m'cap of £12.1)Does anyone have any thoughts on this as an investment. I'm actually in a small profit having bought loads at 5p. I like the people and believe in the product. I'd like to load up with more but, as yet, no one has proven that a demand exists for what it's offering. All opinions welcome. |
Posted at 25/4/2023 18:23 by idomeneo This might not be the bottom but I bought £5k here. There are lots of negatives, but there is time and cash (it qualifies as a Ben Graham Net Net which has returned 460% over the last 11 years). They may need a stock market oriented CEO who is prepared to do the things which creates the noise to get people interested, but in the meantime we have a results day plus hopefully an "Investor Meet Company" or similar following that. There was no liquidity for that £5k, so it is just available to private punters at this price. No guarantee at all of a long term win, but that doesn't have to matter. Could tank to 4p if they come with nothing to say. |
Posted at 19/1/2023 08:53 by wan The market is still unimpressed with Trellus, despite some positive news flow and change etc, but the market obviously wants more than a just a positive backdrop in terms of prospects.To repeat: Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS. I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. But the dynamics appear to be on the cusp of change with regard to pharma developments related to IBD. From the Trellus Health Half-year Report - "We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform." Pharmaceutical competition looks set to increase, which may increase the attention, and intensify the ongoing discussions with Trellus - January 17, 2023 Digesting 2022 and looking forward to 2023 in IBD therapeutics The past year has seen quite a few new developments in inflammatory bowel disease therapy. Other important developments to anticipate in 2023 include the introduction of as many as eight adalimumab biosimilars to the U.S. market, which almost certainly will drive the price of adalimumab down, and the potential approvals of subcutaneous Entyvio (vedolizumab, Takeda) and Inflectra (infliximab-dyyb, Celltrion) for the treatment of IBD. These therapeutics have already been approved in multiple other regions including Europe. It will be interesting to see what effect the availability of the adalimumab biosimilars and subcutaneous vedolizumab and infliximab-dyyb will have on treatment algorithms, especially if the cost differences are significant. I suspect it will take time for us to “digest” all these new developments, and the publication of real-world experiences with these new agents will help shape our clinical practice. Here’s looking to 2023! Full article - Food for thought: Dr. Dubinsky is co-founder and equity owner in a MiTest Health, which received a licensing fee from Takeda for CDPATH. Dr. Dubinsky has received compensation from both Takeda Pharmaceutical and Prometheus Laboratories as a consultant. In addition to Takeda, Dr. Dubinsky also serves as a paid consultant for other pharmaceutical companies that develop and/or manufacture treatments for inflammatory bowel disease (IBD). Dr. Dubinsky is co-founder and equity owner of two start-up companies involved in IBD healthcare, Trellus Health and GoDoRun. |
Posted at 06/12/2022 09:43 by wan Quiet here with the shares trading, by my estimate (cash at year-end in Dec equating to c10p per share), at a relatively small premium to expected cash levels and which provide a cash runway into 2025 which is based on managements conservative assumptions only.I note that Trellus has updated/revamped their website - Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS. I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. A reminder - "We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform." |
Posted at 18/10/2022 10:23 by robin_lemer The last presentation by the management is a mus to listen to. Major points:The biggest group of gastroenterologists in the US will announce on 22/23 October that the first port of call for people with IBS or IBD is Trellus. There are over 32 million people in US with one of the conditions .Their new CEO is a most respected docotr in this field.They also said there will be many positive announcements going forward. Additionally they have reduced their burn rate considerably. I like many on this site am a holder from when they first floated and therefore am holding paper losses however have bought more shares at 9.5p and 13p. See the presentation through Investor meet site well worth it |
Posted at 30/8/2022 07:32 by faz At 7p mdown from 70p a passive investor will need a return of 10 times to get back what they invested, just to be flat. Anyone subscribing to the fundraise in May would have lost over 80% of their investment. Like Renalytix there appears to be no business acuman behind the idea and like Renalyix the stock market has been used as a money-raid and for no other reason. |
Posted at 12/7/2022 07:57 by wan We're thrilled to announce the official nationwide launch of Trellus Health for all people age 16+ in the US living with Crohn's disease and Ulcerative Colitis -Trellus Health appear to be in an area that may be somewhat 'differentiated' from the digital health crowd - Market downturn dampens digital health funding, M&A in 2022. These sectors raked in the most cash By Heather Landi Jul 12, 2022 "Venture investors raised record funds last year, meaning they will have capital to deploy for years to come," the researchers wrote. "Meanwhile, startups are using this market moment to reconsider valuations, trim costs, and, in some cases, people, and refine go-to-market strategies. We foresee these startup adjustments activating savvy M&A deal-makers in H2 2022, with pairings between complementary digital health companies likely leading H2 2022 M&A activity." Digital mental healthcare also continued to be a hot sector, raising a combined $1.3 billion in the first half of 2022 to again reach the top-funded clinical spot, led by Lyra’s $235 million raise in January. However, of that $1.3 billion just $300 million closed in Q2 2022—possibly signaling a slowdown. Full story - |
Posted at 08/7/2022 08:46 by wan The Accidental GastroPsychologist: Building A Business From Behavior Support07 Jul 2022 INTERVIEWS Executive Summary Digital health platforms that offer personalized support are gaining traction in the market, both from patients and investors. Trellus Health is connecting IBD patients with resilience methodologies that enable disease management at lower healthcare costs. Its co-founder Laurie Keefer talks to In Vivo about scaling up the business for greater reach within the market. You need to sign up for a free trial to get access. |
Posted at 10/6/2022 14:20 by sharw adobbing - just checked my ii a/c and still not there, today being the 8th working day since they should have been released. Googled Broadway Nominees to see if I could contact them and all I could get was Companies House who have them as a dormant company!!I have emailed Walbrook who do Investor Relations for both EKF and TRLS. trellus@walbrookpr.c |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
